Search: id:"swepub:oai:DiVA.org:uu-220791" >
Plasma YKL-40 in Pa...
-
Tarpgaard, Line S.
(author)
Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab : RESULTS from the NORDIC VII Study
- Article/chapterEnglish2014
Publisher, publication year, extent ...
-
2014-02-03
-
Public Library of Science (PLoS),2014
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-220791
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-220791URI
-
https://doi.org/10.1371/journal.pone.0087746DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:128302755URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background: We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with first-line oxaliplatin and 5-flourouracil with or without cetuximab. Patients and Methods: A total of 566 patients in the NORDIC VII Study were randomized 1:1:1 to arm A (Nordic FLOX), arm B (Nordic FLOX + cetuximab), or arm C (Nordic FLOX + cetuximab for 16 weeks followed by cetuximab alone as maintenance therapy). Pretreatment plasma samples were available from 510 patients. Plasma YKL-40 was determined by ELISA and dichotomized according to the age-corrected 95% YKL-40 level in 3130 healthy subjects. Results: Pretreatment plasma YKL-40 was elevated in 204 patients (40%), and median YKL-40 was higher in patients with mCRC than in healthy subjects (age adjusted, P < 0.001). Patients with elevated YKL-40 had shorter PFS than patients with normal YKL-40 (7.5 vs. 8.2 months; hazard ratio (HR) = 1.27 95% confidence interval (CI) 1.05-1.53 P = 0.013) and shorter OS (16.8 vs. 23.9 months; HR = 1.33, 1.04-1.69, P = 0.024). Multivariate Cox analysis demonstrated that elevated pretreatment YKL-40 was an independent biomarker of short OS (HR = 1.12, 1.01-1.25, P = 0.033). The ratio of the updated plasma YKL-40 (i.e. level after 1, 2, 8 weeks of treatment, and at end of treatment compared to the baseline level) was associated with OS (HR = 1.27, 1.06-1.52, P = 0.011). Conclusions: Plasma YKL-40 is an independent prognostic biomarker in patients with mCRC treated with first-line oxaliplatin-based therapy alone or combined with cetuximab.
Added entries (persons, corporate bodies, meetings, titles ...)
-
Guren, Tormod K.
(author)
-
Glimelius, BengtUppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap(Swepub:uu)bengglim
(author)
-
Christensen, Ib J.
(author)
-
Pfeiffer, Per
(author)
-
Kure, Elin H.
(author)
-
Sorbye, Halfdan
(author)
-
Ikdahl, Tone
(author)
-
Yilmaz, Mette
(author)
-
Johansen, Julia S.
(author)
-
Tveit, Kjell Magne
(author)
-
Uppsala universitetInstitutionen för radiologi, onkologi och strålningsvetenskap
(creator_code:org_t)
Related titles
-
In:PLOS ONE: Public Library of Science (PLoS)9:2, s. e87746-1932-6203
Internet link
Find in a library
-
PLOS ONE
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Tarpgaard, Line ...
-
Guren, Tormod K.
-
Glimelius, Bengt
-
Christensen, Ib ...
-
Pfeiffer, Per
-
Kure, Elin H.
-
show more...
-
Sorbye, Halfdan
-
Ikdahl, Tone
-
Yilmaz, Mette
-
Johansen, Julia ...
-
Tveit, Kjell Mag ...
-
show less...
- Articles in the publication
-
PLOS ONE
- By the university
-
Uppsala University
-
Karolinska Institutet